Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Dec;28(6):507-32.
doi: 10.1023/a:1014414520282.

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

Affiliations

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

D E Mager et al. J Pharmacokinet Pharmacodyn. 2001 Dec.

Abstract

Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.

PubMed Disclaimer

References

    1. Pharm Res. 1997 Apr;14(4):546-9 - PubMed
    1. J Pharm Sci. 1998 Jun;87(6):732-7 - PubMed
    1. J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S65-68 - PubMed
    1. Cancer Res. 1987 Jun 1;47(11):2986-9 - PubMed
    1. J Pharm Pharmacol. 1980 Jul;32(7):471-7 - PubMed

Publication types

MeSH terms

LinkOut - more resources